<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Candida vulvovaginitis in adults: Recurrent infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Candida vulvovaginitis in adults: Recurrent infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Candida vulvovaginitis in adults: Recurrent infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jack D Sobel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1770189531"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vulvovaginal candidiasis (VVC) is one of the most common causes of vulvovaginal itching and discharge. The disorder is characterized by inflammation in the setting of <em>Candida</em> species. Treatment is indicated for the relief of symptoms. While most females will experience a sporadic <em>Candida</em> infection, a small percentage of patients will experience recurrent infection.</p><p>This topic will discuss the treatment of recurrent vulvovaginal candidiasis (RVVC). Related topics on the clinical presentation and diagnosis of vulvovaginal candidiasis, treatment of sporadic infection, and the general approach to patients with vaginitis are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.</p><p class="headingAnchor" id="H2364924694"><span class="h1">CLINICAL POINTS</span></p><p class="headingAnchor" id="H2063364367"><span class="h2">Definition</span><span class="headingEndMark"> — </span>Recurrent vulvovaginal candidiasis (RVVC) is defined as three or more episodes of symptomatic infection within one year; this definition is mainly based on expert opinion and is a change from the prior definition of four or more episodes in one year [<a href="#rid1">1-5</a>].</p><p class="headingAnchor" id="H4192549821"><span class="h2">Need for laboratory testing</span><span class="headingEndMark"> — </span>Vaginal cultures should always be obtained to confirm the diagnosis of RVVC and identify non-albicans <em>Candida</em> species (most commonly <em>C. glabrata</em> and <em>C. krusei</em>, but there are others), if present. The role of molecular tests for diagnosis and management of RVVC has not been fully elucidated. (See  <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H2635670260"><span class="h2">Asymptomatic patients</span><span class="headingEndMark"> — </span>Asymptomatic patients with VVC identified for other reasons (ie, nucleic acid amplification test [NAAT] or culture for evaluation of vaginal discharge, pap smear) do not require treatment [<a href="#rid6">6</a>]; 10 to 20 percent of reproductive-age females harbor <em>Candida</em> species and, in the absence of symptoms, these patients do not require therapy [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H851776181"><span class="h2">Testing for HIV infection</span><span class="headingEndMark"> — </span>Human immunodeficiency virus (HIV) testing of patients diagnosed solely with RVVC is not justified given that RVVC is a common condition in individuals without HIV infection and that most cases occur in uninfected people. The microbiology of vulvovaginal candidiasis is similar for HIV-infected and HIV-uninfected women [<a href="#rid6">6</a>]. Vulvovaginal candidiasis occurs more frequently and has greater persistence, but not greater severity, in HIV-infected patients with very low CD4 counts and high viral load; however, this population is likely to manifest other acquired immune deficiency syndrome-related sentinel conditions [<a href="#rid8">8</a>].</p><p>Those with risk factors for acquisition of HIV should be counseled and offered screening. These risk factors are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H4043680352"><span class="h1">EPIDEMIOLOGY AND PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Recurrent disease is usually due to a relapse from a persistent vaginal reservoir of organisms or endogenous reinfection with identical strains of susceptible <em>C. albicans</em> [<a href="#rid9">9</a>]; however, rarely, a new strain of <em>Candida</em> is responsible for the infection. Most people with RVVC are otherwise healthy and the pathway(s) behind relapse are not fully understood. Contributing factors have been identified and potential mechanisms are under study.</p><p class="headingAnchor" id="H850683752"><span class="h2">Disease frequency</span><span class="headingEndMark"> — </span>Estimating the incidence and prevalence of RVVC is challenging because the symptoms are not exclusive to <em>Candida </em>infection, many individuals self-treat, and treatment is often empiric. In an internet survey study of over 7000 patients across seven countries, the estimated probability of RVVC after an episode of VVC, by age 50, ranged from 14 to 28 percent, with a mean of 23 percent [<a href="#rid10">10</a>]. An earlier survey study that defined RVVC as ≥4 infections over 12 months reported a 9 percent prevalence [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H605007823"><span class="h2">Intrinsic factors</span><span class="headingEndMark"> — </span>Contributory factors that are inherent to the patient and therefore unchangeable include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – Longitudinal DNA-typing studies suggest that, in most people, recurrent disease is due to relapse from a persistent vaginal reservoir of organisms or endogenous reinfection with the identical strain of susceptible <em>C. albicans</em> [<a href="#rid9">9,12</a>]. Infection due to a different <em>Candida</em> species (eg, <em>C. glabrata</em>) have been reported in 10 to 20 percent of patients with RVVC [<a href="#rid3">3</a>]. Risk factors are apparent in only a minority of those with recurrent disease. (See  <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altered immune response</strong> – Evidence has accumulated linking or defining an association of RVVC with vaginal mucosal immune hyperreactivity to the fungus [<a href="#rid13">13,14</a>]. This suggests the occurrence of dysregulated immune reactivity in the pathogenesis of RVVC [<a href="#rid15">15</a>]. Vaginal hyperreactivity involves interleukin (IL)-4-, IL-10-, and IL-22-producing regulatory T cells. IL-17 may play a role in controlling <em>C. albicans</em> infection as it induces vaginal epithelial cells to produce antimicrobial peptides but its role in human disease is unclear. In mice, the role of IL-17 in protection against mucosal <em>Candida</em> infections has been established in the oral cavity [<a href="#rid16">16</a>]. In humans, studies in patients with mucocutaneous candidiasis and RVVC have confirmed the genetic basis for these infections. Different mutations and polymorphisms in innate immune genes alter the vaginal mucosal immune response against <em>Candida</em> [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic polymorphisms</strong> – Multiple genetic polymorphisms have been identified in conjunction with RVVC and more are likely to be elucidated [<a href="#rid18">18,19</a>]. As examples, RVVC has been associated with decreased in vivo concentration of mannose-binding lectin (MBL) and increased concentration of IL-4 [<a href="#rid20">20</a>]. Two specific gene polymorphisms, variants in the MBL and IL-4 alleles, can account for this finding in some individuals. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mannose-binding lectin (MBL)</strong> – The prevalence of a variant MBL gene is higher in patients with RVVC than in controls without candidiasis [<a href="#rid21">21-23</a>]. Since the direct interaction of MBL with <em>C. albicans </em>is an important component of the host's ability to resist candidiasis, impairment of this interaction in MBL-deficient individuals, such as those with certain MBL polymorphisms, appears to predispose these individuals to recurrent vulvovaginal candidal infection [<a href="#rid20">20,21,24-26</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Interleukin-4 (IL-4)</strong> – In general, those with RVVC mount a strong inflammatory response when exposed to small amounts of <em>Candida</em>, whereas unaffected individuals may not mount any inflammatory response and remain asymptomatic. IL-4 blocks the anti-<em>Candida</em> response mediated by macrophages; thus, elevated IL-4 levels result in inhibition of local defense mechanisms [<a href="#rid27">27,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial vaginosis</strong> – In some patients, recurrent BV infection precedes RVVC infection. While antibiotic treatment of BV likely contributes to yeast infection, there is some thought that the dysbiosis and inflammatory changes associated with BV are risk factors for RVVC infection as well [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/131928.html" rel="external">"Bacterial vaginosis: Recurrent infection"</a>.)</p><p></p><p class="headingAnchor" id="H2698568934"><span class="h2">External triggers</span><span class="headingEndMark"> — </span>In contrast to the intrinsic factors above, external factors may initiate an attack of acute vaginitis. In our experience, antibiotic use (most common), sexual activity, recent bacterial vaginosis, and diet can trigger acute vaginitis in some patients. Genetic susceptibility to <em>Candida</em> infection may be necessary for antibiotics to trigger an attack, which would explain why antibiotic use does not result in <em>Candida</em> VVC in all patients following drug exposure. Other drugs that may predispose to RVVC include immunosuppressants, 17-β estradiol, and sodium-glucose cotransporter receptor-2 (SGLT2) inhibitors [<a href="#rid30">30-32</a>].</p><p class="headingAnchor" id="H3428986964"><span class="h1">INITIAL DRUG TREATMENT</span><span class="headingEndMark"> — </span>The aims of treatment are initial relief and continued suppression of symptoms. The clinician must choose both the drug and duration of therapy. For nonpregnant patients, we generally take the following approach:</p><p class="headingAnchor" id="H818923630"><span class="h2">Nonpregnant</span><span class="headingEndMark"> — </span>We take the following approach to treatment of nonpregnant persons with RVVC  (<a class="graphic graphic_algorithm graphicRef141431" href="/z/d/graphic/141431.html" rel="external">algorithm 1</a>):</p><p class="headingAnchor" id="H3156930633"><span class="h3">Fluconazole</span><span class="headingEndMark"> — </span>We treat <strong>nonpregnant</strong> patients with oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> induction therapy followed by extended oral fluconazole maintenance (six months or longer) [<a href="#rid3">3,29,33-40</a>]. The role of maintenance therapy is suppression of symptoms and not eradication of organisms [<a href="#rid29">29,41</a>]. We prefer oral fluconazole to other azoles (ie, <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">oteseconazole</a>) or <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a> as fluconazole is generally well tolerated, easy to use, low cost, and readily available. While oteseconazole appears to have higher long-term efficacy, it has many restrictions to use and is higher cost [<a href="#rid29">29,42</a>]. Patients with fluconazole allergy or intolerance can be treated with ibrexafungerp.</p><p class="headingAnchor" id="H2442711461"><span class="h4">Empiric regimen</span><span class="headingEndMark"> — </span><em>Candida albicans</em> is the causative organism in 80 to 90 percent of patients with RVVC [<a href="#rid3">3</a>]. We take the following approach for patients with confirmed <em>C. albicans</em> or those whose isolate test results are not yet available  (<a class="graphic graphic_algorithm graphicRef141431" href="/z/d/graphic/141431.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial extended </strong><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a><strong> regimen </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction </strong>– <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a>, 150 mg, orally every 72 hours for three doses</p><p></p><p class="bulletIndent2">followed by</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance </strong>– <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a>, 150 mg, orally once per week for six months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trial of drug discontinuation</strong> – After six months, the drug is stopped and the patient is observed for sustained remission or symptom relapse (up to 55 percent of patients experience symptom relapse, typically within six months) [<a href="#rid35">35</a>]. Patients who remain asymptomatic are observed. Those with symptom relapse undergo repeat testing and targeted treatment. (See <a class="local">'Symptom recurrence'</a> below.)</p><p></p><p class="headingAnchor" id="H643936077"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Treatment with extended oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> results in greater sustained remission compared with placebo but is similar to that of topical azoles [<a href="#rid36">36</a>]. During maintenance treatment, more than 80 percent of patients report controlled symptoms and improved quality of life [<a href="#rid33">33,43</a>]. However, symptoms recur in more than half of patients after stopping maintenance [<a href="#rid41">41</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Compared with placebo</strong> – In a meta-analysis of four trials including 518 RVVC patients treated for initial infection, six months of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> maintenance resulted in fewer clinical recurrences compared with placebo maintenance (17 versus 63 percent, relative risk [RR] 0.29, 95% CI 0.14-0.62) [<a href="#rid36">36</a>]. However, by 12 months (ie, six months after stopping fluconazole maintenance therapy), fluconazole treatment effect was sustained but less pronounced compared with placebo (59 versus 77 percent, respectively, RR 0.77, 95% CI 0.68-0.88). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Compared with topical azoles</strong> – In meta-analysis of three trials totaling 106 RVVC patients treated for recurrent infection, clinical recurrence rates were statistically similar at 6 and 12 months of follow-up [<a href="#rid36">36</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Six months</strong> – Clinical recurrence rates at the end of six months of treatment with either oral or topical azole were 21 and 12 percent, respectively (RR 1.66, 95% CI 0.83-3.31).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Twelve months</strong> – Clinical recurrence rates at the end of 12 months (six months of maintenance treatment followed by six months of observation) for oral or topical treatment were 47 and 49 percent (RR 0.95, 95% CI 0.71-1.27). </p><p></p><p class="headingAnchor" id="H828167999"><span class="h4">Adverse effects and monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory monitoring generally not indicated</strong> – Given the safety profile of low-dose <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, most experts do not suggest any laboratory monitoring; however, if other oral imidazoles (<a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>) are used, particularly if taken daily, then monitoring liver function tests is recommended. Idiosyncratic hepatotoxicity secondary to ketoconazole therapy is a concern but rare in this setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential drug interactions</strong> – Although drug interactions are reported with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and several oral agents (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>), such interactions are extremely unlikely with maintenance fluconazole due to the low plasma concentrations accompanying the once-weekly 150 mg dosing regimen. Accordingly, no additional testing is needed.</p><p></p><p class="headingAnchor" id="H755719739"><span class="h3">Oteseconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">Oteseconazole</a> is an azole antifungal drug for use in individuals with RVVC; this agent is more potent against <em>Candida</em> species, including <em>Candida glabrata</em>, compared with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid29">29,42,44-46</a>]. Its use is limited by drug restrictions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Restrictions</strong> – <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">Oteseconazole</a> use is valuable but limited only to patients who are postmenopausal, have undergone bilateral tubal ligation, or have undergone hysterectomy. It should <strong>not</strong> be used in patients of reproductive potential, including those who could become pregnant, are pregnant, or are lactating. Concerns for embryo-fetal toxicity are based on rat studies that reported retinal abnormalities in offspring and because of the long half-life (138 days) of the drug [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing options</strong> – While two dosing regimens are available [<a href="#rid44">44</a>], the single-drug approach is generally preferred for simplicity  (<a class="graphic graphic_algorithm graphicRef141431" href="/z/d/graphic/141431.html" rel="external">algorithm 1</a>). <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">Oteseconazole</a> should be taken with food to aid absorption.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Single-drug regimen</strong> – <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">Oteseconazole</a> 600 mg orally on day 1, oteseconazole 450 mg orally on day 2, and, starting on day 14, oteseconazole 150 mg orally once a week for 11 weeks (ie, once a week dosing during weeks 2 through 12) [<a href="#rid42">42</a>]. The regimen is available in a blister pack that indicates the dose and timing [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dual-drug regimen </strong>– The dual-drug regimen involves initial induction treatment with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> followed by maintenance suppression with <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">oteseconazole</a>. Dosing is as follows [<a href="#rid44">44</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Day 1, day 4, and day 7: <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> 150 mg orally </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Days 14 through 20: <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">Oteseconazole</a> 150 mg orally once daily for 7 days </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Beginning on day 28: <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">Oteseconazole</a> 150 mg orally once a week (ie, every 7 days) for 11 weeks (ie, weeks 4 through 14) [<a href="#rid44">44</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– Initial data from three trials suggest that <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">oteseconazole</a> (induction and maintenance) treatment is at least as good as <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, and likely better, but data directly comparing the two drugs are not yet available. In three clinical trials involving a total of 656 patients randomized to induction treatment followed by maintenance with oteseconazole or placebo, 12-month recurrence rates ranged from 4 to 7 percent for oteseconazole compared with 39 to 43 percent for placebo [<a href="#rid44">44,47</a>]. Additionally, oteseconazole treatment resulted in a greater mean time to RVVC recurrence compared with placebo (46 to 47 weeks compared with 28 to 33 weeks) [<a href="#rid47">47</a>]. The efficacy of extended oteseconazole compared with extended fluconazole is not yet known.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – In the initial drug trials, the most commonly reported adverse reactions were headache (7.4 percent) and nausea (3.6 percent) [<a href="#rid44">44</a>].</p><p></p><p class="headingAnchor" id="H2786371017"><span class="h3">Ibrexafungerp</span><span class="headingEndMark"> — </span>Extended treatment with <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a>, an oral triterpenoid drug, is an option for suppression of RVVC for patients who have not responded to azoles, not tolerated azoles, or have an azole-resistant infection  (<a class="graphic graphic_algorithm graphicRef141431" href="/z/d/graphic/141431.html" rel="external">algorithm 1</a>). While ibrexafungerp offers another treatment option, drug availability and cost may limit use.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Restrictions</strong> – <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">Ibrexafungerp</a> should <strong>not</strong> be used by pregnant or lactating individuals [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">Ibrexafungerp</a> provides a non-azole oral drug treatment option. The induction and maintenance doses are the same. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction </strong>– <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">Ibrexafungerp</a> 300 mg orally (two 150 mg tablets) taken approximately 12 hours apart (ie, 300 mg taken in the morning and again in the evening) [<a href="#rid48">48</a>].  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance</strong> – <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">Ibrexafungerp</a> 300 mg orally (two 150 mg tablets) taken twice in one day is repeated every four weeks for a total of six dosing days (ie, extended treatment for six months) [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In a phase 3 trial evaluating patients with RVVC treated with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> followed by extended treatment with either <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a> (n = 130) or placebo (n = 130), more patients in the ibrexafungerp arm remained without evidence of RVVC (65.4 versus 53.1 percent, respectively) at six-month test of cure (study week 24) [<a href="#rid48">48</a>]. However, long-term benefit of treatment is not yet known as follow-up was limited to three months post-treatment rather than the typical six months. In addition, as the study population mainly included patients wi<em>th C. albicans</em>, it is not known if patients with non-albicans <em>Candida</em> isolates, which constitute 10 to 15 percent of usual isolates, will similarly experience prophylactic benefit [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Common side effects included headaches and gastrointestinal disturbances (diarrhea, nausea) [<a href="#rid48">48</a>].</p><p></p><p class="headingAnchor" id="H4255532528"><span class="h2">Pregnant</span><span class="headingEndMark"> — </span>For pregnant persons with test-confirmed RVVC, we treat with extended courses of <strong>topical</strong> azoles only  (<a class="graphic graphic_algorithm graphicRef141478" href="/z/d/graphic/141478.html" rel="external">algorithm 2</a>). Patients require both induction and maintenance suppressive treatment. Longer courses of induction therapy followed by maintenance for the duration of pregnancy may be required to adequately suppress symptoms. Patients are reassessed after delivery.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs and dosing</strong> – Drug selection is based on prior patient response (if any) as well as drug availability and cost. Data specific to pregnant persons are generally limited. Once symptoms are controlled for several days, then the patient is changed to maintenance suppressive therapy. The aim is to use the lowest maintenance dose and frequency that keeps the patient symptom-free. Should symptoms recur while on therapy, induction treatment is repeated and then followed by maintenance with the drug, dose, and frequency that adequately suppressed symptoms.</p><p></p><p class="bulletIndent1">Options include  (<a class="graphic graphic_algorithm graphicRef141478" href="/z/d/graphic/141478.html" rel="external">algorithm 2</a>) [<a href="#rid5">5,29,37</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">Clotrimazole</a> 1% cream </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Induction – 1 applicatorful (approximately 5 g) in vagina daily for 7 to 14 days </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Maintenance – 1 applicatorful (approximately 5 g) in vagina two to three times a week for duration of pregnancy</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">Clotrimazole</a> 2% cream is also reasonable. At this dose, duration of induction therapy is three to five days, as needed to control symptoms. This is followed by maintenance at a frequency that controls symptoms.</p><p></p><p class="bulletIndent2"><strong>Or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">Miconazole</a> 2% cream </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Induction – 1 applicatorful (approximately 5 g) in vagina daily for 7 to 14 days</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Maintenance – 1 applicatorful (approximately 5 g) in vagina two to three times a week OR <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a> 1200 mg suppository in vagina once weekly for duration of pregnancy</p><p></p><p class="bulletIndent2">Other <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a> regimens include miconazole 4% cream and high-dose suppository. Induction with miconazole 4% cream is given daily for three to five days, as needed to control symptoms. This is followed by maintenance with miconazole 4% cream at a frequency that controls symptoms (typically 1 to 3 times a week). Alternately, miconazole 1200 mg vaginal suppository can be used once a week for the duration of the pregnancy. </p><p></p><p class="bulletIndent2"><strong>Or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">Nystatin</a> suppository 100,000 units (may require preparation by a compounding pharmacy).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Induction – One suppository in vagina for 14 nights   </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Maintenance – Vaginal suppository use is slowly tapered to the lowest frequency that controls the patient's symptoms. Patients whose symptoms are controlled on the nightly regimen reduce frequency to every other night for several weeks. If symptoms remain controlled, the frequency is reduced again to two to three times a week. If symptoms worsen at any point, the patient returns to the frequency that controlled symptoms. Treatment is continued for the duration of pregnancy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs we avoid</strong> – We do <strong>not</strong> use oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">oteseconazole</a>, or <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a> due to concerns for fetal harm. (See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Pregnancy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> has been associated with increased risk of pregnancy loss and possibly congenital malformations [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">Oteseconazole</a> and <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a> are not for use in pregnancy or lactation because of concerns for potential harm based on animal data [<a href="#rid44">44,48</a>]. </p><p></p><p class="bulletIndent1">Additionally, <a class="drug drug_general" data-topicid="9978" href="/z/d/drug information/9978.html" rel="external">terconazole</a> labelling states "it should not be in the first trimester" unless use is essential to the welfare of the patient and it "may bed be used during the second and third trimester if potential benefits outweighs the possible risks to the fetus" [<a href="#rid50">50</a>]. We do <strong>not</strong> use boric acid or <a class="drug drug_general" data-topicid="139621" href="/z/d/drug information/139621.html" rel="external">dequalinium</a> chloride because safety of long-term use has not been established. Pregnant patients have been given short courses (&lt;24 hours) of dequalinium chloride for reduction of group B streptococcus infection [<a href="#rid51">51</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Potential side effects of topical therapy include burning, redness, and irritation. </p><p></p><p class="headingAnchor" id="H2213766878"><span class="h2">Lactating</span><span class="headingEndMark"> — </span>Lactating patients may use oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> but not <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">oteseconazole</a> or <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a> [<a href="#rid44">44,48,52-55</a>]. Topical <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a> and <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a> are minimally absorbed from the vagina and thus are considered reasonable for use in lactating patients [<a href="#rid56">56,57</a>]. As <a class="drug drug_general" data-topicid="9178" href="/z/d/drug information/9178.html" rel="external">butoconazole</a>, <a class="drug drug_general" data-topicid="9998" href="/z/d/drug information/9998.html" rel="external">tioconazole</a>, and <a class="drug drug_general" data-topicid="9978" href="/z/d/drug information/9978.html" rel="external">terconazole</a> have not been studied during lactation, miconazole or clotrimazole use is preferred [<a href="#rid58">58-60</a>].</p><p class="headingAnchor" id="H882219032"><span class="h1">PREFERENCE FOR EXTENDED VERSUS EPISODIC TREATMENT</span><span class="headingEndMark"> — </span>We suggest extended treatment rather than episodic. Patients generally prefer low-intensity prophylactic maintenance therapy to treatment of each recurrence (which requires repeat testing and induction). Our typical regimen is induction therapy with oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> followed by six months of maintenance with weekly fluconazole. Additional details for fluconazole dosing and efficacy are presented below. (See <a class="local">'Fluconazole'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extended duration of treatment</strong> – Support for an extended duration of treatment comes from a meta-analysis and other small trials [<a href="#rid33">33,36</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Six-month recurrence risk (active therapy)</strong> – Extended treatment with a combination of azole drugs (oral or topical) rather than placebo or no treatment reduced both clinical recurrence risk (23 versus 65 percent, relative risk [RR] 0.36, 95% CI 0.21-0.63, 607 participants) and mycological recurrence risk (29 versus 71 percent, RR 0.44, 95% CI 0.25-0.78, 568 participants) [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2">As an example of the anticipated absolute effect, VVC recurrence over six months would be expected in:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>233 per 1000 patients receiving extended azole treatment</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>647 per 1000 patients receiving placebo or no treatment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Twelve-month recurrence risk (active therapy followed by observation)</strong> – Analysis of studies comparing six months of active azole treatment (oral or topical) followed by six months of observation, the clinical recurrence risk remained lower for the treatment group but became more comparable with placebo or no treatment (63 versus 78 percent, RR 0.80, 95% CI 0.72-0.89, 585 participants) [<a href="#rid36">36</a>]. Mycological recurrence risk was similar between the groups based on a smaller sample size (75 versus 85 percent, RR 0.90, 95% CI 0.79-1.03, 189 participants). </p><p></p><p class="bulletIndent2">As an example of the anticipated absolute effect, recurrence at 12 months would be expected in:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>625 per 1000 patients receiving extended azole treatment </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>781 per 1000 patients receiving placebo or no treatment </p><p></p><p class="bulletIndent1">It is important to recognize that the trials included in the meta-analysis had small sample sizes with important methodologic limitations. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Episodic and other alternatives to extended treatment</strong> – Alternate regimens include variations of episodic treatment or treatment duration.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Episodic treatment as needed</strong> – Rather than use extended maintenance therapy, patients may treat each recurrent episode as an acute uncomplicated infection  (<a class="graphic graphic_table graphicRef71686" href="/z/d/graphic/71686.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. This approach may appeal to patients who prefer fewer overall days of medication but is generally a higher intensity approach as patients must be retested and retreated with conventional therapy for each episode. (See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Uncomplicated infection'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Longer duration of episodic treatment</strong> – In this approach, each recurrent episode is treated with longer duration of conventional therapy (eg, topical azole for 7 to 14 days <strong>or</strong> <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 150 mg orally on day 1, day 4, and day 7) [<a href="#rid3">3,37,61</a>]. Some patients may prefer repeat treatments of 7 to 14 days total duration rather six or months or more of maintenance therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Longer induction followed by maintenance</strong> –<strong> </strong>Several societies recommend 10 to 14 days of induction therapy with a topical or oral azole followed by <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> 150 mg once per week for six months (<a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a> 200 mg vaginal cream twice weekly is a nonoral alternative) [<a href="#rid40">40,62</a>]. </p><p></p><p class="headingAnchor" id="H159512356"><span class="h1">SYMPTOM RECURRENCE</span><span class="headingEndMark"> — </span>Management of confirmed RVVC depends on the timing of the recurrence relative to use of maintenance therapy. More than half of patients will experience symptom recurrence following cessation of maintenance prophylaxis because the underlying causal factors that contributed to lower genital tract infection remain unchanged [<a href="#rid36">36</a>]. Maintenance therapy is prescribed for symptom control but is not curative.</p><p class="headingAnchor" id="H2078316517"><span class="h2">Retest and confirm compliance</span><span class="headingEndMark"> — </span>When symptoms recur, patients are again tested to confirm yeast infection and exclude other causes of symptoms [<a href="#rid29">29</a>]. If yeast are reconfirmed, empiric treatment is restarted, as discussed above. Additionally, testing is performed to identify non-albicans species (eg, culture) and drug-resistant organisms (for patients with history of drug-resistant infection or whose symptoms recur on <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> maintenance). As drug-resistance testing takes additional time and generally increases cost, we do not perform such testing routinely. (See <a class="local">'Need for laboratory testing'</a> above.)</p><p>The <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> regimen is repeated and tailored as needed once isolate test results are available. (See <a class="local">'Empiric regimen'</a> above.)</p><p class="headingAnchor" id="H2402006688"><span class="h2">Relapse off therapy</span><span class="headingEndMark"> — </span>More than 50 percent of treated patients will experience symptom recurrence as soon as <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> maintenance is withdrawn (ie, fluconazole-dependent RVVC) [<a href="#rid29">29,36</a>]. As recurrence off therapy is generally <strong>not</strong> related to fluconazole resistance, fluconazole treatment is reasonably repeated. </p><p>Patients may elect: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Episodic treatment</strong> – Treat each recurrence episode with oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Oral fluconazole'</a>.)</p><p></p><p><strong>Or</strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction and continued maintenance</strong> – Patients are again treated with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> induction followed by maintenance for continued suppression of symptoms. In this scenario, maintenance therapy may be extended to a year or more. This approach is mainly based on clinical experience as few studies assess beyond six months of therapy [<a href="#rid29">29,36</a>]. (See <a class="local">'Fluconazole'</a> above.)</p><p></p><p>The ultimate duration of maintenance therapy is determined by the patient's preferences around continuing suppressive treatment (or stopping and observing) and prior response. In our experience, patients generally prefer low-intensity maintenance therapy to treatment of every recurrence (which requires repeat testing and repeat induction therapy). (See <a class="local">'Fluconazole'</a> above.)</p><p class="headingAnchor" id="H2870247417"><span class="h2">Relapse on maintenance therapy</span><span class="headingEndMark"> — </span>For patients whose relapse occurred during <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> maintenance, we confirm the drug was being used consistently and correctly. We perform isolate and drug sensitivity testing because relapse that occurs during fluconazole maintenance is concerning for fluconazole-resistant organisms (including non-albicans <em>Candida</em> or fluconazole-resistan<em>t C. albicans</em>). </p><p class="headingAnchor" id="H1401562001"><span class="h3">Non-albicans Candida species</span><span class="headingEndMark"> — </span>Non-albicans <em>Candida sp</em>ecies have been observed in 10 to 20 percent of patients with RVVC [<a href="#rid3">3</a>]. Non-albicans <em>Candida sp</em>ecies most commonly include <em>C. glabrata an</em>d <em>C. krusei, b</em>ut there are others. </p><p>Treatment of RVVC with non-albicans species is extended to six months or longer  (<a class="graphic graphic_algorithm graphicRef141536" href="/z/d/graphic/141536.html" rel="external">algorithm 3</a>). Drug selection is driven by the species, drug contraindications and interactions, patient preferences for oral or vaginal treatment, availability, and cost. We typically offer <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a> first because it has demonstrated efficacy, is generally available, and has few contraindications [<a href="#rid29">29</a>]. Other therapies include <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a>, <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a>, and <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, although supporting data are very limited. <a class="drug drug_general" data-topicid="139621" href="/z/d/drug information/139621.html" rel="external">Dequalinium</a> chloride is an alternate therapy for RVVC available in some countries but we do not have clinical experience with this drug [<a href="#rid63">63,64</a>].</p><p>The treatment of non-albicans <em>Candida</em> is discussed in detail in related content. (See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Non-albicans Candida species'</a>.)</p><p class="headingAnchor" id="H3758768259"><span class="h3">Azole-resistant infection</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect</strong> – Azole resistance is suspected when symptoms and signs are refractory while on appropriately dosed and used azole drugs (any azole) or as breakthrough infection while on maintenance <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> therapy. Drug-resistance testing is performed to identify azole-resistant organisms. </p><p></p><p class="bulletIndent1">In persons with RVVC, there is some evidence that repeated and prolonged use of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> can infrequently select for fluconazole resistance in <em>C. albicans</em> strains previously susceptible to fluconazole, which limits the treatment options. Differences in genetic mutations have been reported between fluconazole-susceptible and fluconazole-resistant <em>Candida</em> species [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> –<strong> </strong>The rare patient with azole-resistant organisms is treated similarly to patients with non-albicans infections  (<a class="graphic graphic_algorithm graphicRef141536" href="/z/d/graphic/141536.html" rel="external">algorithm 3</a>). Azole-resistant species are typically <em>C. albicans</em>. (See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Non-albicans Candida species'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assess drug minimum inhibitory concentration (MIC)</strong> – In patients with refractory vulvovaginal candidiasis with persistently positive <em>C. albicans</em> cultures, susceptibility tests utilizing MICs to various antifungals can be measured by using the broth microdilution method conducted in accordance with Clinical and Laboratory Standards Institution criteria and breakpoints [<a href="#rid65">65</a>]. A vaginal sample is cultured and the organisms are then tested. (See  <a class="medical medical_review" href="/z/d/html/465.html" rel="external">"Antifungal susceptibility testing"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increase azole dose based on MIC</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>MIC &gt;2 to 4</strong> – These patients may respond to higher doses of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or, in some cases, <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>. In a study of 25 patients with refractory VVC and a <em>C. albicans</em> isolate with fluconazole MIC ≥2 micrograms/mL, those with fluconazole MIC values of 2 or 4 micrograms/mL were treated successfully by increasing fluconazole dose to 200 mg twice weekly [<a href="#rid66">66</a>]. In the author's experience, a higher dose of fluconazole has not been effective for patients with MIC &gt;4 micrograms/mL [<a href="#rid29">29</a>]. These individuals should be evaluated for cross-resistance to itraconazole and ketoconazole as some patients can be treated effectively with long-term maintenance daily imidazole therapy. However, use of itraconazole or ketoconazole requires intermittent hepatic function testing. Idiosyncratic hepatotoxicity secondary to ketoconazole therapy is a concern but rare in this setting.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>MIC &gt;4</strong> – These patients have fluconazole-resistant infection. Treatment options include <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a> suppositories, <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> suppositories, oral <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a>, or <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">oteseconazole</a>. Selection is based on availability and contraindications. Treatment duration is based on sporadic versus recurrent infection. Sporadic infections are treated for 7 to 14 days (longer duration for more severe symptoms). Patients with recurrent infection may require treatment for six months or more. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of pan-azole resistance</strong> – Azole resistance has been reported in non-<em>C. albicans</em> infections [<a href="#rid67">67</a>]. Persons with severe RVVC infection and high-level pan-azole resistance are treated with <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a>, <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a>, or <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> suppositories [<a href="#rid68">68</a>]. Dosing is as discussed in each drug discussion. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See <a class="local">'Ibrexafungerp'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>(See <a class="local">'Vaginal boric acid'</a> below.)</p><p></p><p class="headingAnchor" id="H2170828125"><span class="h1">LIFESTYLE</span></p><p class="headingAnchor" id="H867877273"><span class="h2">Behavioral changes</span><span class="headingEndMark"> — </span>Attempts should be made to eliminate or reduce medical risk factors for infection (eg, improve glycemic control, switch to lower estrogen dose oral contraceptive). As an adjunct to drug therapy, it is reasonable to change behavioral factors that could exacerbate symptoms, although there is little evidence that this is helpful (eg, avoid panty liners, douching, tight clothing, pantyhose, cranberry juice, and topical lubricants) [<a href="#rid29">29,62,69</a>]. (See  <a class="medical medical_review" href="/z/d/html/5452.html" rel="external">"Candida vulvovaginitis: Clinical manifestations and diagnosis", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H234598471"><span class="h2">Probiotics and diet</span><span class="headingEndMark"> — </span>Probiotic use has not been associated with long-term clinical or mycological cure [<a href="#rid70">70</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lactobacilli</strong> – There is no evidence that individuals with RVVC have vaginal flora deficient in lactobacilli, and therefore we do not recommend use of probiotic lactobacilli [<a href="#rid34">34,62,71,72</a>]. Although there is a popular belief that ingestion or vaginal administration of yogurt or other agents containing live lactobacilli decreases the rate of <em>Candida</em> colonization and symptomatic relapse, the few studies have methodologic limitations (eg, no control group, short follow-up) and small numbers of subjects [<a href="#rid73">73-77</a>]. The value of administering live lactobacilli to patients with recurrent infection has been refuted in other studies [<a href="#rid69">69,78</a>], and this approach should be considered unproven. The quality of probiotics varies worldwide; in the United States, these products are not standardized and are often of poor quality. The US Food and Drug Administration (FDA) has cautioned against using probiotics with bacteria or yeast in immunocompromised patients [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary changes</strong> – In the absence of controlled studies evaluating the role of diet in preventing and controlling VVC, no specific diets are recommended. Occasional patients report precipitation of episodic vaginitis after consuming beer or refined sugar products, especially when consumed in excess. Under these circumstances, avoidance of recognized precipitating food items or alcohol is prudent but frequently insufficient to resolve symptoms.</p><p></p><p class="headingAnchor" id="H3979781370"><span class="h2">Sexual and psychosocial health</span><span class="headingEndMark"> — </span>Patients with RVVC may develop sexual dysfunction and/or relationship difficulties [<a href="#rid62">62,80</a>]. Clinicians should inquire about the impact of RVVC on other aspects of the patient's life and provide access to appropriate counseling and support. (See  <a class="medical medical_review" href="/z/d/html/5485.html" rel="external">"Overview of sexual dysfunction in females: Management"</a>.)</p><p class="headingAnchor" id="H2859062865"><span class="h2">SGLT2 inhibitor drugs</span><span class="headingEndMark"> — </span>Sodium-glucose cotransporter receptor-2 (SGLT2) inhibitors have been associated with RVVC [<a href="#rid30">30</a>]. We discuss alternate diabetes treatment options with patients using these drugs and their providers.</p><p class="headingAnchor" id="H1377589251"><span class="h1">TREATMENTS WITH LIMITED USE</span></p><p class="headingAnchor" id="H1892842679"><span class="h2">Topical azoles</span><span class="headingEndMark"> — </span>Topical azoles are commonly used in pregnant patients and as an alternate to oral therapy. Patients can reasonably use topical azole induction and maintenance rather than oral azole treatment as small trials report similar efficacy [<a href="#rid36">36</a>]. (See <a class="local">'Efficacy'</a> above.)</p><p class="headingAnchor" id="H2947643028"><span class="h2">Vaginal boric acid</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">Vaginal boric acid</a> is used for a limited set of patients, including those with azole-resistant <em>C. albicans</em>, intolerance or allergy to azoles, or non-albicans <em>Candida</em> [<a href="#rid81">81,82</a>]. There is no role for vaginal boric acid in treatment of RVVC to usual <em>C albicans</em>. <strong>Boric acid can cause death if taken orally.</strong> </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Patients initially try induction treatment alone. Those in whom recurrence occurs quickly repeat induction treatment and then start maintenance therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction</strong> – <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">Vaginal boric acid</a> (600 mg suppositories) daily for two to three weeks [<a href="#rid3">3,67,83</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance</strong> – <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">Vaginal boric acid</a> (600 mg suppositories daily) for two to three months. The patient then slowly titrates down the dose. As data-supported regimens are lacking, we have the patient reduce the frequency gradually. Patients who do well with several months of daily vaginal boric acid then reduce to every other day for a few weeks, then once a week for a few weeks, and then stop. If symptoms recur, the process is repeated and the patient maintained on the lowest frequency of vaginal boric acid that suppressed symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug safety</strong> – There are limited safety data on long-term use of <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a>, which may cause local irritation and has the potential for toxicity (including death) if taken orally by accident. Sex partners who have contact with vaginal boric acid could develop irritation or dermatitis of the exposed area, but the duration of risk following treatment is not known. While an observational study reported that 35 RVVC patients tolerated extended boric acid maintenance therapy (average duration 13 months) with minimal irritation, data from large trials are not available [<a href="#rid83">83,84</a>].</p><p></p><p class="headingAnchor" id="H1919130042"><span class="h2">Gentian violet</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="8749" href="/z/d/drug information/8749.html" rel="external">gentian violet</a> was widely used prior to the availability of the topical azole intravaginal antifungal creams and suppositories. This agent has largely been abandoned because azole antimycotics are more effective (potent) [<a href="#rid85">85</a>] and because gentian violet is messy and inconvenient (eg, it permanently stains clothes). However, it is useful to treat vulvar itching and for occasional refractory cases of vulvovaginal candidiasis, especially those demonstrating azole resistance [<a href="#rid86">86</a>]. The drug is applied to affected areas of both the vulva and vagina daily for 10 to 14 days.</p><p class="headingAnchor" id="H2392833149"><span class="h2">Vaginal nystatin</span><span class="headingEndMark"> — </span>Vaginal <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> may be used as an alternative to <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a>. Dosage is 100,000 units daily (as a pessary or suppository). Vaginal nystatin is given nightly for 14 nights for induction treatment. Patients with recurrent infection require maintenance therapy for six months or more. Dosing for all patients is the same as for pregnant persons. (See <a class="local">'Pregnant'</a> above.)</p><p class="headingAnchor" id="H3939619446"><span class="h2">Therapies not in use</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunotherapy</strong> – Local vaginal hypersensitivity to <em>C. albicans</em> has been proposed as the cause of recurrent infection in some patients [<a href="#rid87">87,88</a>]. Immunotherapy of VVC for both prevention and treatment is a therapeutic approach that has been investigated [<a href="#rid89">89</a>]. A prophylactic vaccine would need to induce a host immune response against fungal virulence traits without altering the tolerance/inflammation balance of the vaginal environment, whereas a therapeutic vaccine indicated for patients with RVVC could enhance or rectify tolerance/inflammation imbalance in the vagina [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">Imiquimod</a> – Imiquimod, a topical Toll-like receptor 7 agonist that activates immune cells and is typically used to treat condylomata acuminata, has been used for RVVC in at least one case report [<a href="#rid91">91</a>]. Until larger studies supporting the safety and efficacy of this approach are available, we do not advise using imiquimod for RVVC. The impact of imiquimod treatment of condylomata acuminata on candidiasis is not known.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral </strong><a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> – Decreasing gastrointestinal <em>Candida</em> colonization by oral administration of nystatin does not prevent recurrent symptomatic vaginal infection [<a href="#rid1">1</a>].</p><p></p><p class="headingAnchor" id="H4265161710"><span class="h1">UNIQUE POPULATIONS</span><span class="headingEndMark"> — </span>Discussions addressing patients with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> allergy, sex partners, lactating individuals, patients taking <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>, male partners with postcoital symptoms, and patients with <em>Candida</em> as an incidental finding are presented in related content. (See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Unique populations'</a>.)</p><p class="headingAnchor" id="H3889885683"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111629.html" rel="external">"Society guideline links: Gynecologic infectious diseases (non-sexually transmitted)"</a>.)</p><p class="headingAnchor" id="H1382680559"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15467.html" rel="external">"Patient education: Vulvovaginal yeast infection (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/8402.html" rel="external">"Patient education: Vaginal yeast infection (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H4083928162"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and clinical points</strong> – Recurrent vulvovaginal candidiasis (RVVC) is defined as three or more episodes of symptomatic infection within one year. RVVC should be confirmed as the cause of symptoms prior to treatment and non-albicans <em>Candida</em> species should be identified, if present. (See <a class="local">'Clinical points'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– The aims of treatment are initial relief and continued suppression of symptoms. Asymptomatic individuals with incidentally identified <em>Candida</em> species do not require treatment. (See <a class="local">'Initial drug treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonpregnant patients</strong> – For nonpregnant patients, we take the following approach  (<a class="graphic graphic_algorithm graphicRef141431" href="/z/d/graphic/141431.html" rel="external">algorithm 1</a>):  </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Choice of agent</strong> – We suggest oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> rather than other drugs  (<a class="graphic graphic_algorithm graphicRef141431" href="/z/d/graphic/141431.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Extended fluconazole treatment is associated with longer disease-free periods and longer time to relapse compared with placebo. <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">Oteseconazole</a> or <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a> are reasonable treatment alternatives but use is limited by restriction criteria, availability, and cost. Topical azole drugs have demonstrated efficacy but patients generally prefer extended treatment with oral than vaginal drugs. (See <a class="local">'Fluconazole'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dosing</strong> – For nonpregnant patients, we prescribe  (<a class="graphic graphic_algorithm graphicRef141431" href="/z/d/graphic/141431.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent3"><strong>Induction</strong> – <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> 150 mg orally every 72 hours for three doses (ie, days 1, 3, and 7)</p><p></p><p class="bulletIndent3">followed by</p><p></p><p class="bulletIndent3"><strong>Maintenance</strong> – <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> 150 mg orally once per week for six months</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Trial off medication</strong> – After six months, the patient stops the drug and observes for sustained remission or symptom relapse. Approximately half of patients will experience sustained remission. (See <a class="local">'Empiric regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnant</strong> <strong>persons</strong> – Pregnant patients require both induction and maintenance suppressive treatment. For those with test-confirmed RVVC, we treat with extended courses of <strong>topical</strong> drugs only  (<a class="graphic graphic_algorithm graphicRef141478" href="/z/d/graphic/141478.html" rel="external">algorithm 2</a>). Longer courses of induction therapy followed by maintenance for the duration of pregnancy may be required to adequately suppress symptoms. (See <a class="local">'Pregnant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extended versus episodic treatment</strong> – For individuals with confirmed RVVC due to suspected or proven <em>Candida albicans</em>, we suggest extended treatment to provide sustained symptom relief rather than treat individual episodes as they occur (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Patients generally prefer low-intensity maintenance therapy to treatment of every recurrence (which requires repeat testing and repeat induction therapy). (See <a class="local">'Preference for extended versus episodic treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeat testing for symptom recurrence</strong> – If symptoms recur, we repeat laboratory testing to confirm infection and identify species. Additionally, for patients with a history of fluconazole-resistant organisms, we repeat drug-susceptibility/resistance testing. As no treatment is clearly superior to another, we take the following treatment approach based on the assumption that most isolates a<em>re C. albicans</em> and tailor treatment as isolate data become available. (See <a class="local">'Empiric regimen'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relapse off </strong><strong>fluconazole</strong><strong> maintenance </strong>– If RVVC is confirmed, we suggest 12 months or longer of oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> maintenance rather than six months of maintenance therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In our experience, azole resistance is an unlikely mechanism of disease recurrence in patients who initially respond to extended fluconazole treatment but then recur off treatment (ie, fluconazole-dependent RVVC). (See <a class="local">'Fluconazole'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Relapse during </strong><strong>fluconazole</strong><strong> maintenance</strong> – For patients with confirmed relapse during <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> maintenance who are consistently and correctly using the drug, isolate and drug -resistance testing guide treatment. Options include <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a>, <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">ibrexafungerp</a>, and <a class="drug drug_general" data-topicid="138579" href="/z/d/drug information/138579.html" rel="external">oteseconazole</a>. Drug selection is driven by patient preferences, contraindications, drug-drug interactions, availability, and cost.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Non-albicans </strong><strong><em>Candida</em></strong><strong> species</strong> – Non-albicans <em>Candida</em> species most commonly include <em>C. glabrata</em> and <em>C. krusei</em>, but there are others. Patients with non-albicans species require a different treatment approach  (<a class="graphic graphic_algorithm graphicRef141536" href="/z/d/graphic/141536.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Non-albicans Candida species'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Azole drug resistance</strong> – Azole resistance is determined with susceptibility tests measuring minimum inhibitory concentrations to various antifungal drugs. The rare patient with azole-resistant organisms is treated similarly to patients with non-albicans <em>Candida</em> infections  (<a class="graphic graphic_algorithm graphicRef141536" href="/z/d/graphic/141536.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Non-albicans Candida species'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluconazole</strong><strong> intolerance or allergy</strong> – <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">Ibrexafungerp</a> is the preferred treatment for patients with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> allergy (uncommon) or intolerance. Alternately, individuals with fluconazole allergy, including angioedema and severe rash, can receive topical azoles (eg, <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">miconazole</a> or <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a>) or <a class="drug drug_general" data-topicid="134822" href="/z/d/drug information/134822.html" rel="external">vaginal boric acid</a>. (See  <a class="medical medical_review" href="/z/d/html/115170.html" rel="external">"Candida vulvovaginitis in adults: Treatment of acute infection", section on 'Allergy to fluconazole'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985; 152:924.</a></li><li><a class="nounderline abstract_t">Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016; 214:15.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Nyirjesy P, Brookhart C, Lazenby G, et al. Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. Clin Infect Dis 2022; 74:S162.</a></li><li class="breakAll">International Society for the Study of Vulvovaginal Disease recommendations for the diagnosis and treatment of vaginitis, Vieira-Baptista P, Stockdale CK, Sobel J (Eds), Admedic, Lisbon 2023.</li><li><a class="nounderline abstract_t">Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961.</a></li><li><a class="nounderline abstract_t">National guideline for the management of vulvovaginal candidiasis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75 Suppl 1:S19.</a></li><li><a class="nounderline abstract_t">Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 2003; 101:548.</a></li><li><a class="nounderline abstract_t">Vazquez JA, Sobel JD, Demitriou R, et al. Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis 1994; 170:1566.</a></li><li><a class="nounderline abstract_t">Blostein F, Levin-Sparenberg E, Wagner J, Foxman B. Recurrent vulvovaginal candidiasis. Ann Epidemiol 2017; 27:575.</a></li><li><a class="nounderline abstract_t">Foxman B, Muraglia R, Dietz JP, et al. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 2013; 17:340.</a></li><li><a class="nounderline abstract_t">Lockhart SR, Reed BD, Pierson CL, Soll DR. Most frequent scenario for recurrent Candida vaginitis is strain maintenance with "substrain shuffling": demonstration by sequential DNA fingerprinting with probes Ca3, C1, and CARE2. J Clin Microbiol 1996; 34:767.</a></li><li><a class="nounderline abstract_t">Yano J, Noverr MC, Fidel PL Jr. Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins. Cytokine 2012; 58:118.</a></li><li><a class="nounderline abstract_t">Rosati D, Bruno M, Jaeger M, et al. Recurrent Vulvovaginal Candidiasis: An Immunological Perspective. Microorganisms 2020; 8.</a></li><li><a class="nounderline abstract_t">De Luca A, Carvalho A, Cunha C, et al. IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis. PLoS Pathog 2013; 9:e1003486.</a></li><li><a class="nounderline abstract_t">Mengesha BG, Conti HR. The Role of IL-17 in Protection against Mucosal Candida Infections. J Fungi (Basel) 2017; 3.</a></li><li><a class="nounderline abstract_t">Jaeger M, Plantinga TS, Joosten LA, et al. Genetic basis for recurrent vulvo-vaginal candidiasis. Curr Infect Dis Rep 2013; 15:136.</a></li><li><a class="nounderline abstract_t">Jaeger M, Pinelli M, Borghi M, et al. A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis. Sci Transl Med 2019; 11.</a></li><li><a class="nounderline abstract_t">Esfahani A, Omran AN, Salehi Z, et al. Molecular epidemiology, antifungal susceptibility, and ERG11 gene mutation of Candida species isolated from vulvovaginal candidiasis: Comparison between recurrent and non-recurrent infections. Microb Pathog 2022; 170:105696.</a></li><li><a class="nounderline abstract_t">Babula O, Lazdāne G, Kroica J, et al. Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40:1258.</a></li><li><a class="nounderline abstract_t">Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92:43.</a></li><li><a class="nounderline abstract_t">Donders GG, Babula O, Bellen G, et al. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 2008; 115:1225.</a></li><li><a class="nounderline abstract_t">Hammad NM, El Badawy NE, Nasr AM, et al. Mannose-Binding Lectin Gene Polymorphism and Its Association with Susceptibility to Recurrent Vulvovaginal Candidiasis. Biomed Res Int 2018; 2018:7648152.</a></li><li><a class="nounderline abstract_t">Ip WK, Lau YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2004; 190:632.</a></li><li><a class="nounderline abstract_t">Lillegard JB, Sim RB, Thorkildson P, et al. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 2006; 193:1589.</a></li><li><a class="nounderline abstract_t">Giraldo PC, Babula O, Gonçalves AK, et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 2007; 109:1123.</a></li><li><a class="nounderline abstract_t">Cenci E, Romani L, Mencacci A, et al. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol 1993; 23:1034.</a></li><li><a class="nounderline abstract_t">Essner R, Rhoades K, McBride WH, et al. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989; 142:3857.</a></li><li class="breakAll">Sobel J, Wayne State University School of Medicine, 2023, personal communication.</li><li><a class="nounderline abstract_t">Forman JL, Mercurio MG. Vulvar Pruritus in Postmenopausal Diabetic Women With Candidiasis Secondary to Sodium-Glucose Cotransporter Receptor-2 Inhibitors. J Low Genit Tract Dis 2023; 27:68.</a></li><li><a class="nounderline abstract_t">Bataineh MTA, Cacciatore S, Semreen MH, et al. Exploring the effect of estrogen on Candida albicans hyphal cell wall glycans and ergosterol synthesis. Front Cell Infect Microbiol 2022; 12:977157.</a></li><li><a class="nounderline abstract_t">Kumwenda P, Cottier F, Hendry AC, et al. Estrogen promotes innate immune evasion of Candida albicans through inactivation of the alternative complement system. Cell Rep 2022; 38:110183.</a></li><li><a class="nounderline abstract_t">Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 351:876.</a></li><li><a class="nounderline abstract_t">Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. Obstet Gynecol 2020; 135:e1. Reaffirmed 2022.</a></li><li><a class="nounderline abstract_t">Collins LM, Moore R, Sobel JD. Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans. J Low Genit Tract Dis 2020; 24:48.</a></li><li><a class="nounderline abstract_t">Cooke G, Watson C, Deckx L, et al. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2022; 1:CD009151.</a></li><li><a class="nounderline abstract_t">Saxon Lead Author GDGC, Edwards A, Rautemaa-Richardson R, et al. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019). Int J STD AIDS 2020; 31:1124.</a></li><li><a class="nounderline abstract_t">Reef SE, Levine WC, McNeil MM, et al. Treatment options for vulvovaginal candidiasis, 1993. Clin Infect Dis 1995; 20 Suppl 1:S80.</a></li><li><a class="nounderline abstract_t">Donders G, Bellen G, Byttebier G, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008; 199:613.e1.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. J Low Genit Tract Dis 2018; 22:382.</a></li><li><a class="nounderline abstract_t">Martens MG, Maximos B, Degenhardt T, et al. Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections. Am J Obstet Gynecol 2022; 227:880.e1.</a></li><li><a class="nounderline abstract_t">Nguyen Y, Lee A, Fischer G. Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy. Australas J Dermatol 2017; 58:e176.</a></li><li class="breakAll">VIVJOA (oteseconazole) [package insert]. Durham, NC: Mycovia Pharmaceuticals Inc, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf (Accessed on April 29, 2022).</li><li><a class="nounderline abstract_t">Sobel JD, Nyirjesy P. Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis. Future Microbiol 2021; 16:1453.</a></li><li><a class="nounderline abstract_t">Brand SR, Sobel JD, Nyirjesy P, et al. A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. Clin Infect Dis 2021; 73:e1518.</a></li><li><a class="nounderline abstract_t">Sobel JD, Donders G, Degenhardt T, et al. Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis. NEJM Evid 2022.</a></li><li class="breakAll">Brexafemme- ibrexafungerp tablet, film coated. US Food and Drug Administration (FDA) approved product information. Revised November 30, 2022. US National Library of Medicine. www.dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on April 21, 2023).</li><li><a class="nounderline abstract_t">Mølgaard-Nielsen D, Svanström H, Melbye M, et al. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA 2016; 315:58.</a></li><li class="breakAll">Terconazole- terconazole cream. US Food and Drug Administration (FDA) approved product information. Revised March, 2021. US National Library of Medicine. www.dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on April 26, 2023).</li><li><a class="nounderline abstract_t">Hijona JJ, Carballo AL, Sánchez MS, et al. Vaginal antiseptics reduce the risk of perinatal infection with group B streptococci. J Matern Fetal Neonatal Med 2019; 32:2741.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.</a></li><li class="breakAll">Fluconazole. Drugs and Lactation Database (LactMed). Revised October 2018. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501922/?term=fluconazole (Accessed on April 07, 2023).</li><li><a class="nounderline abstract_t">Kaplan YC, Koren G, Ito S, Bozzo P. Fluconazole use during breastfeeding. Can Fam Physician 2015; 61:875.</a></li><li class="breakAll">Drugs and Lactation Database (LactMed). US National Library of Medicine. US National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK501922/ (Accessed on May 09, 2023).</li><li class="breakAll">Miconazole. Drugs and Lactation Database (LactMed). Revised September 2022. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501234/ (Accessed on April 07, 2023).</li><li class="breakAll">Clotrimazole. Drugs and Lactation Database (LactMed). Revised September 2022. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501211/ (Accessed on April 07, 2023).</li><li class="breakAll">Tioconazole. Drugs and Lactation Database (LactMed). Revised October 2018. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501426/ (Accessed on April 07, 2023).</li><li class="breakAll">Butoconazole. Drugs and Lactation Database (LactMed). Revised October 2018. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501424/ (Accessed on April 07, 2023).</li><li class="breakAll">Terconazole. Drugs and Lactation Database (LactMed). Revised October 2018. US National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501428/ (Accessed on April 07, 2023).</li><li><a class="nounderline abstract_t">Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</a></li><li><a class="nounderline abstract_t">Brown L, Chamula M, Weinberg S, et al. Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes. J Fungi (Basel) 2022; 8.</a></li><li><a class="nounderline abstract_t">Mendling W, Weissenbacher ER, Gerber S, et al. Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review. Arch Gynecol Obstet 2016; 293:469.</a></li><li><a class="nounderline abstract_t">Frey Tirri B. Antimicrobial topical agents used in the vagina. Curr Probl Dermatol 2011; 40:36.</a></li><li class="breakAll">Clinical and Laboratory Standards Institute. Performance standards for antimibrobial susceptibility testing. Nineteenth informational supplement. Approved standard M100–S19. Wayne (PA): Clinical and Laboratory Standards Institute; 2009.</li><li><a class="nounderline abstract_t">Marchaim D, Lemanek L, Bheemreddy S, et al. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012; 120:1407.</a></li><li class="breakAll">Guidelines for the Prevention and Treatment of opportunistic Infections in Adults and Adolescents with HIV. U.S Department of Health and Human Services. May 2020. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new (Accessed on May 10, 2023).</li><li><a class="nounderline abstract_t">Danby CS, Boikov D, Rautemaa-Richardson R, Sobel JD. Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use. Antimicrob Agents Chemother 2012; 56:1403.</a></li><li><a class="nounderline abstract_t">Patel DA, Gillespie B, Sobel JD, et al. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: Results of a prospective cohort study. Am J Obstet Gynecol 2004; 190:644.</a></li><li><a class="nounderline abstract_t">Xie HY, Feng D, Wei DM, et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev 2017; 11:CD010496.</a></li><li><a class="nounderline abstract_t">Sobel JD, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol 1996; 34:2497.</a></li><li><a class="nounderline abstract_t">McClelland RS, Richardson BA, Hassan WM, et al. Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. J Infect Dis 2009; 199:1883.</a></li><li><a class="nounderline abstract_t">Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992; 116:353.</a></li><li><a class="nounderline abstract_t">Shalev E, Battino S, Weiner E, et al. Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. Arch Fam Med 1996; 5:593.</a></li><li><a class="nounderline abstract_t">Collins EB, Hardt P. Inhibition of Candida albicans by Lactobacillus acidophilus. J Dairy Sci 1980; 63:830.</a></li><li><a class="nounderline abstract_t">Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: A review. J Antimicrob Chemother 2006; 58:266.</a></li><li><a class="nounderline abstract_t">Martinez RC, Franceschini SA, Patta MC, et al. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol 2009; 48:269.</a></li><li><a class="nounderline abstract_t">Witt A, Kaufmann U, Bitschnau M, et al. Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: A randomised trial. BJOG 2009; 116:1499.</a></li><li class="breakAll">US Food and Drug Administration. MedWatch safety alerts for human medical products. Available at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ (Accessed on November 13, 2017).</li><li><a class="nounderline abstract_t">Bradfield Strydom M, Walpola RL, McMillan S, et al. Lived experience of medical management in recurrent vulvovaginal candidiasis: a qualitative study of an uncertain journey. BMC Womens Health 2022; 22:384.</a></li><li><a class="nounderline abstract_t">Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: The clinical evidence. J Womens Health (Larchmt) 2011; 20:1245.</a></li><li><a class="nounderline abstract_t">Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother 2018; 19:971.</a></li><li><a class="nounderline abstract_t">File B, Sobel R, Becker M, Nyirjesy P. Fluconazole-Resistant Candida albicans Vaginal Infections at a Referral Center and Treated With Boric Acid. J Low Genit Tract Dis 2023; 27:262.</a></li><li><a class="nounderline abstract_t">Powell A, Ghanem KG, Rogers L, et al. Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis. Sex Transm Dis 2019; 46:810.</a></li><li><a class="nounderline abstract_t">Chayachinda C, Thamkhantho M, Ngamsakulrungroj P, et al. Effect of intravaginal gentian violet for acute vaginal candidiasis treated with a single dose oral fluconazole: a randomised controlled trial. J Obstet Gynaecol 2022; 42:2190.</a></li><li><a class="nounderline abstract_t">White DJ, Johnson EM, Warnock DW. Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. Genitourin Med 1993; 69:112.</a></li><li><a class="nounderline abstract_t">Rigg D, Miller MM, Metzger WJ. Recurrent allergic vulvovaginitis: Treatment with Candida albicans allergen immunotherapy. Am J Obstet Gynecol 1990; 162:332.</a></li><li><a class="nounderline abstract_t">Rosati D, Bruno M, Jaeger M, et al. An Exaggerated Monocyte-Derived Cytokine Response to Candida Hyphae in Patients With Recurrent Vulvovaginal Candidiasis. J Infect Dis 2022; 225:1796.</a></li><li><a class="nounderline abstract_t">Magliani W, Conti S, Cassone A, et al. New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol Med 2002; 8:121.</a></li><li><a class="nounderline abstract_t">Cassone A. Vulvovaginal Candida albicans infections: Pathogenesis, immunity and vaccine prospects. BJOG 2015; 122:785.</a></li><li><a class="nounderline abstract_t">Kofler L, Nagele U, Kofler H. Recurrent vulvovaginal candidiasis: successful suppression with imiquimod. J Dermatol 2013; 40:851.</a></li></ol></div><div id="topicVersionRevision">Topic 141182 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3895958" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26164695" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Recurrent vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35416967" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35416967" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17560449" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Vulvovaginal candidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10616376" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : National guideline for the management of vulvovaginal candidiasis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12636961" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7995997" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28927765" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Recurrent vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23486072" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8815082" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Most frequent scenario for recurrent Candida vaginitis is strain maintenance with "substrain shuffling": demonstration by sequential DNA fingerprinting with probes Ca3, C1, and CARE2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22182685" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cytokines in the host response to Candida vaginitis: Identifying a role for non-classical immune mediators, S100 alarmins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31972980" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Recurrent Vulvovaginal Candidiasis: An Immunological Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23853597" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29371568" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Role of IL-17 in Protection against Mucosal Candida Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23354953" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Genetic basis for recurrent vulvo-vaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31189718" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35921954" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Molecular epidemiology, antifungal susceptibility, and ERG11 gene mutation of Candida species isolated from vulvovaginal candidiasis: Comparison between recurrent and non-recurrent infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15825027" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16256117" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mannose-binding lectin and vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18715406" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29850562" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mannose-Binding Lectin Gene Polymorphism and Its Association with Susceptibility to Recurrent Vulvovaginal Candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243942" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16652289" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470593" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8477799" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2785566" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : IL-4 down-regulates IL-1 and TNF gene expression in human monocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2785566" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : IL-4 down-regulates IL-1 and TNF gene expression in human monocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36129363" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Vulvar Pruritus in Postmenopausal Diabetic Women With Candidiasis Secondary to Sodium-Glucose Cotransporter Receptor-2 Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36268228" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Exploring the effect of estrogen on Candida albicans hyphal cell wall glycans and ergosterol synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34986357" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Estrogen promotes innate immune evasion of Candida albicans through inactivation of the alternative complement system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15329425" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31856123" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31860575" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35005777" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment for recurrent vulvovaginal candidiasis (thrush).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32883171" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7795112" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment options for vulvovaginal candidiasis, 1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18976735" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29975334" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35863457" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27170259" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27170259" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34783586" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32818963" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746458" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746458" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29699432" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vaginal antiseptics reduce the risk of perinatal infection with group B streptococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533352" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Transfer of drugs and other chemicals into human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533352" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Transfer of drugs and other chemicals into human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fluconazole use during breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fluconazole use during breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Fluconazole use during breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Fluconazole use during breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Fluconazole use during breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fluconazole use during breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759844" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fluconazole use during breastfeeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26042815" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sexually transmitted diseases treatment guidelines, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36135648" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Compliance with the Updated BASHH Recurrent Vulvovaginal Candidiasis Guidelines Improves Patient Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26506926" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325838" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Antimicrobial topical agents used in the vagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325838" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Antimicrobial topical agents used in the vagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168767" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fluconazole-resistant Candida albicans vulvovaginitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168767" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fluconazole-resistant Candida albicans vulvovaginitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22232293" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15041994" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: Results of a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29168557" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Probiotics for vulvovaginal candidiasis in non-pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8880507" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19456235" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736766" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8930233" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6771309" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Inhibition of Candida albicans by Lactobacillus acidophilus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16790461" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Probiotics for prevention of recurrent vulvovaginal candidiasis: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19187507" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19583713" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: A randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19583713" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: A randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36123738" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Lived experience of medical management in recurrent vulvovaginal candidiasis: a qualitative study of an uncertain journey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21774671" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Boric acid for recurrent vulvovaginal candidiasis: The clinical evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29932786" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36961480" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Fluconazole-Resistant Candida albicans Vaginal Infections at a Referral Center and Treated With Boric Acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31663976" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35253598" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effect of intravaginal gentian violet for acute vaginal candidiasis treated with a single dose oral fluconazole: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8389723" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2178425" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Recurrent allergic vulvovaginitis: Treatment with Candida albicans allergen immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32702099" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : An Exaggerated Monocyte-Derived Cytokine Response to Candida Hyphae in Patients With Recurrent Vulvovaginal Candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11879772" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : New immunotherapeutic strategies to control vaginal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25052208" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Vulvovaginal Candida albicans infections: Pathogenesis, immunity and vaccine prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23915307" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Recurrent vulvovaginal candidiasis: successful suppression with imiquimod.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
